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ABSTRACT
Objective: The main objective of this research is to develop and validate a simple, specific, precise, sensitive, cost-effective, and rapid reversed-
phase high-performance liquid chromatography method for simultaneous quantification of glucosamine (GLU), diacerein (DIA) and methyl sulfonyl 
methane in bulk and pharmaceutical dosage forms, and micro-sample of rat plasma using ultraviolet (UV) detection, to perform the studies of drug 
dissolution from tablets.
Methods: Sprague-Dawley rats were used for pharmacokinetic study after intravenous administration of the drug samples at dose 5 mg/kg. The drug 
samples were extracted by liquid-liquid extraction technique using acetonitrile, which also acted as a deproteinization agent. The separation of the 
analyte was carried out on a phenomena C18 column with a mobile phase composed of 0.1 % orthophosphoric acid:acetonitrile (80:20 v/v) delivered 
at a flow rate of 1.0 ml/min, and separation has been monitored by a UV detector, at detection of the wavelength of 285 nm.
Results: This method was proven to be linear over a concentration range of 30–450 µg/ml for GLU, 2–30 µg/ml for DIA, and 10–150 µg/ml for methyl 
sulfonyl methane with a correlation coefficient of 0.999. The retention time of GLU, DIA, and methyl sulfonyl methane were 2.89, 6.32, and 9.87 min, 
respectively. Recovery of the drugs was found to be in the range of 98.0–102.0%. Validation results were found to be satisfactory and the method 
applicable for bulk and formulation analysis. Hence, it was evident that the proposed method was said to be a suitable one for the regular analysis and 
quality control of pharmaceutical preparations which contain these active drugs either individually or in combination.
Conclusion: The validation results were in good agreement with acceptable limits. Relative standard deviation values which are less than 2.0% 
are indicating the accuracy and precision of this method. The usefulness of the method is that the common chromatographic conditions have been 
adopted for assay, dissolution, and pharmacokinetic studies. This developed method showed reliable, precise, and accurate results under optimized 
conditions.
Keywords: Glucosamine, Diacerein, Methyl sulfonyl methane, Pharmacokinetics, Dissolution profile.
INTRODUCTION
Glucosamine (GLU) (Fig. 1) is chemically called (3R, 4R, 5S)-3-amino-
6-(hydroxymethyl) oxane-2, 4, 5-triol. It can act as an amino sugar and 
a prominent precursor in the biochemical synthesis of glycosylated 
proteins and lipids [1, 2]. It is found in the hard covering of shellfish [3]. 
It is one of the most common non-vitamin, non-mineral, dietary 
supplements, and natural products. It is used for osteoarthritis, back 
pain, and joint pain.
Diacerein (DIA) (Fig. 2) chemically called 4, 5-bis (acetyloxy)-9,10-
dioxo-2-anthracenecarboxylic acid [4,5]. It is slow-acting drug and is 
used in the treatment of osteoarthritis, analgesic, and nonsteroidal anti-
inflammatory drugs [6-8]. It may be safe on the stomach [9-11]. It can 
inhibit interleukin-1 and retards all pathological processes initiating 
in osteoarthritis [12] and also inhibits superoxide production, chemo 
taxis, and phagocytic activity of neutrophils.
Methylsulfonylmethane (MET) (Fig. 3) can acts as a precursor for 
the synthesis of methionine, cysteine, and sulfur-containing amino 
acids [13]. As it is suggested anti-inflammatory and analgesic effects, 
it has been promoted as a possible supplement for osteoarthritis [14] 
and is used to protect muscles from damage by reducing the amount of 
oxidative stress.
A dissolution test is an important tool for characterizing drug product 
performance and is a vital component of the overall quality control 
program [15,16]. It is used to determine whether a drug the product can 
release its active pharmaceutical ingredients in a timely manner [17]. 
The study of the dissolution rate is observed to be sensitive, reliable, 
and rationale for predicting in vivo drug bioavailability behavior among 
all tests that can be performed on different combinations of drugs.
Literature survey reveals that several methods have been present for the 
estimation of each drug [18-20] and two drugs at a time [21]. However, 
one of the analytical methods for assay has been reported for the 
estimation of GLU, DIA, and MET in pharmaceutical dosage forms [22]. 
However, it is of interest to refer that the studies of dissolution rate and 
relevant kinetic parameters of these active drugs have not yet been 
reported previously so that present research work was undertaken.
The present paper explains the development of method that meets the 
suggested aim: The simple, specific, precise, sensitive, cost-effective, and 
rapid reversed-phase high-performance liquid chromatography (RP-
HPLC) method for simultaneous quantification of GLU, DIA, and MET in 
bulk and pharmaceutical dosage forms, and micro-sample of rat plasma 
using ultraviolet (UV) detection, to carry out drug dissolution studies from 
tablets. The proposed method showed reliable, precise, and accurate results 
under optimized conditions. Hence, this method appears to be appropriate 
for the quality control technique in the pharmaceutical industry.
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2020.v13i12.36547
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Fig. 2:  Chemical structure of diacerein
Fig. 3: Chemical structure of methylsulfonylmethane
Fig. 1: Chemical structure of glucosamine
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EXPERIMENTAL
Reagents and solutions
Pure samples of GLU, DIA, and MET used were obtained from Glenmark 
Pharmaceutical Private Ltd., Andheri (E), Mumbai, India (99.7–99.9% 
purity). All other chemicals such as acetonitrile, orthophosphoric acid, 
and water were of HPLC grade, purchased from Merck (India) Ltd. 
Worli, Mumbai, India.
Instrumentation
Water alliance-2695 chromatographic system equipped with a 
quaternary pump, variable UV, and photodiode-array detection detectors 
were used. For data collection and processing chromatographic 
software, Empower-2.0 has been used. 
Selection of buffer
Simple, economical, and proper acidic buffer were selected like 0.1% 
orthophosphoric acid.
Mobile phase
The mobile phase selected was 0.1% orthophosphoric acid 
buffer:acetonitrile in the ratio of 80:20 (v/v), and the mobile phase was 
degassed before analysis. The selected mobile phase has given sharp peaks 
with low tailing factor (2.0) and also plate count was more than in 2000.
Diluent preparation
The diluent was optimized as a mixture of water and acetonitrile 
(50:50 v/v).
Selection of wavelength
The maximum absorption of the solution of three drugs was scanned 
in the UV region against acetonitrile as blank using a photodiode 







% RSD NMT 2.0 0.26 0.32 0.18
USP tailing NMT 2.0 0.84 0.75 0.65
USP plate count NLT 3000 5628 7458 4514
DIA: Diacereinm GLU: Glucosamine, MET: Methylsulfonylmethane, NMT: Not 
less than, NMT: Not more than
Table 5: Precision data of GLU










Table 3: Recovery data for DIA









Table 4: Recovery data for MET









Table 6: Precision data of DIA










Table 2: Recovery data for GLU






Fig. 4: Photodiode-array detection spectrum for glucosamine, diacerein, and methylsulfonylmethane
Fig. 5: Method developed chromatogram
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Fig. 6: Chromatograms for (a) blank, and (b) placebo
b
a
Fig. 7: Chromatogram for system suitability
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Table 7: Precision data of MET








at a flow rate of 1.0 ml/min. The injection volume was 10 µl with 12 min 
run time and the column the temperature was maintained at 60°C and 
absorbance measured at 285 nm.
Standard solution preparation
300 mg of GLU, 20 mg of DIA, and 100 mg of MET (working standard) were 
accurately measured and transferred into a 100 ml clean and dry volumetric 
flask, about 70 ml of mobile phase was added, sonicated for complete 
dissolution and it was made up to the mark with the diluent. 5.0 ml of this 
solution was diluted to 50 ml with the mobile phase and mixed well.
Sample preparation
Ten tablets were weighed and triturated in a mortar. The tablet powder 
equivalent to 480 mg of active ingredient (sample) presents in ten 
tablets has been transferred into a 100 ml clean and dry volumetric 
flask, 70 ml of diluent was added, sonicated to about 30 min with 
occasional stirring and made up the volume with diluent. From this 
solution, 5.0 ml was diluted to 50 ml with the mobile phase. These 
solutions were filtered through 0.45 µ nylon syringe filter.
RESULTS AND DISCUSSION
The purpose of this study is to develop accurate, specific, cost-effective, 
and a single isocratic HPLC method for the simultaneous quantification 
Table 8: Results of stress degradation studies
Stress condition/duration/solution Degradation (%)
Acid degradation (0.5 N HCl, 1 h) 25
Alkaline degradation (0.5 N NaOH, 1 h) 22
Oxidative degradation (30% H2O2, 80°C 
 for 15 min)
28
Reduction degradation (10% NaHSO4, 80°C  
for 15 min)
27
Thermal degradation (Solid sample, 80°C, 3h) 23
Photolytic degradation (sample expose  
sun light 6 h)
22
spectrophotometer. The spectra of GLU, DIA, and MET (Fig. 4) show 
different λmax, namely, 272.1, 285.1, and 257.9, respectively. 285 
nm was selected as detector wavelength for the proposed method by 
considering the highest response for three drugs.
Chromatographic conditions
HPLC studies have been done on Phenomenex C18 (250 × 4.6 mm, 
5 µm) column. The separations were attained by isocratic elution and 
acetonitrile: H3PO4 (0.1%) (20:80 by volume) as mobile phase delivered 
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Table 9: Results of robustness studies
Change in parameter % RSD
Flow (0.8 ml/min) 0.65
Flow (1.2 ml/min) 0.92
Organic phase composition (+5 %) 0.24
Organic phase composition (-5 %) 0.22
Wavelength (290 nm) 0.74
Wavelength (280 nm) 0.56
RSD: Relative standard deviation
Table 10: Results of stability studies
Stability % Label claim % Deviation
Initial 100.6 0.00
6 h 100.4 0.02
12 h 100.0 0.04
18 h 99.8 0.08
24 h 99.6 1.00
of GLU, DIA, and MET in bulk and pharmaceutical dosage forms, and 
micro-sample of rat plasma using UV detection, and to carry out the 
studies of drug dissolution from tablets. Appropriate wavelengths for 
simultaneous estimation of three drugs were selected according to the 
UV spectra of these compounds.
Method optimization
Development trials were carried out with acidic buffers, methanol, and 
acetonitrile using isocratic and gradient mode. Different stationary 
phases such as phenyl, biphenyl, amino, C4, and C8 were used to analyze 
the method. In addition, the mobile phase composition was modified 
at each trail to enhance the resolution and to achieve good retention 
d
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Fig. 12: Chromatograms for (a) acid degradation, (b) alkali degradation, (c) peroxide degradation, (d) reduction degradation, (e) thermal 
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15 min 32 35 38
30 min 58 60 57
60 min 95 94 96
Recovery 99 98 98
DIA: Diacerein, GLU: Glucosamine, MET: Methylsulfonylmethane
Table 11: Results for pharmacokinetic studies
Time intervals Glu (ng/ml) Dia (ng/ml) MET (ng/ml)
0 h 0.00 0.00 0.00
0.5 h 30.36 38.25 35.47
1.0 h 42.68 45.14 46.32
1.5 h 55.38 58.26 60.32
2.0 h 95.87 93.32 96.21
2.5 h 75.31 70.68 72.47
3.0 h 68.36 60.55 65.32
DIA: Diacerein, GLU: Glucosamine, MET: Methylsulfonylmethane
Method validation
The developed method was validated as per the International Council 
for Harmonization (ICH) guidelines [23-24] with the aspect of system 
suitability, linearity, and range, precision in terms of % relative standard 
deviation (RSD), accuracy in terms of % recovery, and robustness study.
Specificity
It is the capability of the method for the accurate and specific measurement 
of the analyte of interest in the presence of matrix and other components.
Procedure
The solutions of standard, sample, and blank were injected into the 
system and chromatograms were recorded. There was no interference 
of the placebo with the principal peak, which indicates that the 
proposed method was specific. These results are furnished in Fig. 6.
System suitability
System suitability tests were conducted out to check the system 
functioning before or during the analysis. The parameters such as 
retention time, theoretical plate number, tailing factor, peak area, and 
the resolution were monitored for the suitability of the system (Table 1).
Procedure
Six replicate injections of standard solutions were injected and system 
suitability parameters such as theoretical plate number, time, peak 
area, tailing factor, and the resolution were calculated. The results are 
furnished in Fig. 7.
Linearity and range
Linearity is its ability to obtain the test results which are directly 
proportional to the concentration of the analyte in the sample. This 
times. Finally, the chromatographic separation was achieved on a 
phenomena C18 column (250 mm × 4.6 mm, 5 µm particle size) with 
a mobile phase composed of 0.1 % orthophosphoric acid:acetonitrile 
(80:20 v/v) delivered at a flow rate of 1.0 ml/min, and separation was 
monitored by a UV detector, at a detection wavelength of 285 nm. The 
total run time was less than 12 min (Fig. 5).
(Contd...)
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linearity was measured by plotting a calibration curve of peak area 
against their respective concentration.
Procedure
Six different concentrations of the mixture of DIA, GLU, and MET 
prepared for this study. The solutions were injected and calibration 
curves were constructed, showed linear relationship. Peak areas were 
observed. The SD slope, intercept and the coefficient of variation of the 
curves were determined. The regression equations for the calibration 
curve were y=23078x+8841(0.9993) for DIA, y=6055.1x+9171.2 
(0.9993) for GLU and y=17982x+22598 (R2=0.999) for MET. The 
results are furnished in Fig. 8.
Accuracy
Accuracy is in agreement with acceptable true value and actual result. It 
was determined by calculating the recovery of the drugs at three kinds 
of concentration levels.
Procedure
The accuracy was measured at three different concentration levels such 
as 150, 300, and 450 µg/ml of GLU, 10, 20, and 30 µg/ml of DIA and 50, 
100, and 150 µg/ml of MET. As per the test method, the test solution 
was injected 3 times for every spike level and the assay was performed. 
The recovery the percentage was calculated and results were furnished 
in Tables 2-4, (Fig. 9).
Precision
The precision of the analytical procedure demonstrates the closeness 
of an agreement between a series of measurements obtained from 
multiple sampling of homogeneous samples. It has been demonstrated 
by repeatability, reproducibility, and intermediate precision.
Limit of detection (LOD) and limit of quantification (LOQ)
LOD is the smallest the concentration of the analyte which gives the 
measurable response (3.3 σ/S) and LOQ is the smallest concentration of 
the analyte which gives accurately quantified response (10 σ/S), where σ 
is the SD of the response and S is the slope of the calibration plot (Fig. 11).
Procedure
The LOD and LOQ were measured by injecting progressively low 
concentrations of the standard solutions. LOD and LOQ values of 
GLU, DIA, and MET were found to be 0.30 and 3.00 µg/ml, 0.002 and 
0.20 µg/ml, and 0.10 and 1.00 µg/ml, respectively.
Stress degradation
Active drugs were subjected to different stress conditions according to 
ICH guidelines Q1A (R2). Stress degradation studies were performed 
by different types of stress conditions to obtain the degradation of 
about 20%.
Procedure
As per the ICH guidelines, QA1 (R2) stress degradation conditions such as 
thermal, acidic, oxidative, hydrolysis, reduction, and photolytic stresses 
were attempted. There is no interference between the peak and were well 
separated with the resolution at least 1.0 and the purity of the principal 
peaks should pass (Fig. 12). The results are furnished in Table 8.
Procedure
Repeatability  was  calculated  by  injecting  six  replicates  of 
standard solution into the HPLC system. The mean, SD and % RSD 
of  the  peak  areas  were  calculated.  As  per  the  test  method  for 
reproducibility,  six  samples of  the single batch were analyzed.  The 
proposed method has been found to be precise as the percentage of 
RSD  values  was  found  to  be  less  than  2%.  Results  are  furnished  in 
Tables 5-7, (Fig. 10).
(Contd...)
Fig. 14: (a) Chromatogram for stability initial, (b) chromatogram for stability 6 h, (c) chromatogram for stability 12 h, (d) chromatogram 
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Fig. 14: (Continued)
Fig. 15: Diagram for plasma study
e
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Robustness
Deliberate small modifications in the method parameters were done 
and the results were not influenced by various changes in the method 
parameters.
Procedure
The small changes in optimized parameters, such as ±0.2 change in flow 
rate, ±5 change in the mobile phase, and a change of ±5 in wavelength, 
were done to analyze the robustness of the method. There was no 
remarkable impact on retention time, plate count, and tailing factor 
(Fig. 13). The results are furnished in Table 9.
Stability
The standard and the sample solutions were subjected to 24 h stability 
studies. The stability of these solutions was studied and changes in 
area and retention time of the peaks were observed. The results were 
compared with the pattern of the chromatogram of the freshly prepared 
solution.
Procedure
The sample solutions were analyzed initially to 24 h at laboratory 
temperature. Retention time and pea area of the drugs were unchanged. 
No significant degradation was observed within the period sufficient 
for performing the analytical process and the percentage deviation is 
not more than 5% (Fig. 14). The results are furnished in Table 10.
Recovery studies in spiked rat plasma samples
The method of liquid-liquid extraction was utilized to isolate GLU, DIA, 
and MET in rat plasma. Active drug sample was injected into rat body 
and samples have collected at different time periods such as 0, 0.5, 1.0, 
1.5, 2.0, 2.5, and 3.0 h. Before processing, the plasma samples were 
kept at –20°C and allowed to thaw at normal temperature. After gentle 
thawing 100 µl, aliquot plasma sample (respective concentration) was 
added in polypropylene centrifuge tubes, vortexed briefly and 2.5 ml 
of acetonitrile was added. The tubes were vortexed for 10 min and 
then it was centrifuged at 4000 rpm. The supernatant liquid was taken 
carefully transferred into another conical glass tube and completely 
evaporated the organic layer at 40°C. After completion of evaporation, 
these samples were reconstituted with 500 µl of acetonitrile and 
vortexed for 5 min and then the sample was transferred into 
autosampler vials for injection. These samples have been injected in 
developed chromatographic conditions and values were recorded. A 
2nd h the sample reaches the maximum result, suddenly down to 3.0 h 
(Fig. 15). The results are furnished in Table 11.
Dissolution study
The medium of dissolution phosphate buffer (pH 6.8).
Preparation of dissolution media 0.235 M dibasic sodium phosphate 
was taken and pH adjusted to 6.8 with 0.1 N HCl.
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For the dissolution study of GLU, DIA, and MET analysis was performed 
using the above chromatographic conditions with the aid of a paddle 
stirrer type of apparatus in 900 ml of pH 6.8 phosphate buffers at a 
stirring rate of 100 rpm and the temperature was maintained at 37±5°C. 
Accurately weighed and placed one tablet in each of the six dissolution 
vessel containing dissolution media. The samples were collected at 
30, 60 min, and recovery (150 RPM extra 30 min). The samples were 
prepared as per assay test concentration and equal volumes (10 µl) of 
these test solutions were injected into the system with autosampler and 
peaks areas were measured (Table 12).
CONCLUSION
The suggested method of RP-HPLC is simple, specific, precise, sensitive, 
cost-effective, and rapid for the simultaneous quantification of GLU, 
DIA, and MET in bulk and the pharmaceutical dosage forms, and micro-
sample of rat plasma using UV detection, to carry out drug dissolution 
studies from tablets. The validation results were in good agreement 
with acceptable limits. RSD values which are less than 2.0% indicating 
the accuracy and precision of this method. The usefulness of the method 
is that the common chromatographic conditions have been adopted 
for assay, dissolution, and pharmacokinetic studies. This developed 
method showed reliable, precise, and accurate results under optimized 
conditions. Hence, it can be concluded that the proposed method can be 
used for regular analysis of GLU, DIA, and MET in rat plasma samples.
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